August 2023 - The latest oncology investment report is out. Below is a look at all the money that moved across the drug development industry in the US and EU. Each report includes a look at Seed to Series E, IPO and Debt Financing. This gives a good idea of where money is moving to and from.
We then break this down to only focus in Oncology including all the biotech names and focus.
The report is completely free - all I ask is, if you did receive value, please share this or my work with others, helps me greatly.
Click here to download your free report or view inside your browser at the bottom.
Acquisitions:
✅Ikena acquired Pionyr Tx: “The new capital will enable Ikena to expand and accelerate its targeted oncology programs, including both IK-930 and IK-595”
✅EQRx has been bought by Revolution Medicine in an all stock transaction which will further strengthen their RAS(ON) Inhibitor portfolio
✅Novo Nordisk bought Embark Labs to strengthen their early obesity programmes. (non-oncology)
✅ We found a total of 9 other relevant acquisitions within the biopharma drug development space.
Investments:
Biggest Series A-E Investments within Oncology August 2023. Here are some important companies to follow over the next 12 months.
✅Abcuro - $155,000,000 (Series B) : Cytotoxic T Cells precision medicine
✅CCM Biosciences - $25,000,000 (Series A) : KRAS targeting and other
✅Fore Biotherapeutics - $75,000,000 (Series D) : Mutated BRAF inhibition.
✅Georgiamune - $75,000,000 (Series A) : Dual-functioning antibodies within T-regs.
✅Solu Therapeutics - $75,000,000 (Series D) : Cytotxic Targetting Chimera Platform
✅Aulos Bioscience - $20,000,000 (Series A) : CD25 Targetting IL-2 for increased immune activation.
✅ Plus 7 more in the report
Click here to view full report.
